Cdkn2a-flox Mouse

Cdkn2a, encoding p16 and p14, is a crucial tumor suppressor gene [1,2]. It is involved in cell cycle regulation, as p16 inhibits CDK4/6, thus controlling cell proliferation. Its loss is linked to tumor progression, making it of great biological importance in cancer research [1].

Loss of Cdkn2a is a frequent driver of melanoma progression. Pharmacological inhibition of p16 targets CDK4/6, which is a potential therapeutic strategy. Other approaches include exploiting cell cycle deregulation, targeting metabolic rewiring, epigenetically restoring expression, acting on co-deleted gene dependencies, or modulating immune responses [1]. Additionally, CDKN2A is the most common homozygously deleted gene in all human cancers. Tumors often codelete the nearby gene MTAP, creating a dependency on PRMT5, and MTA-cooperative PRMT5 inhibitors show early efficacy in treating CDKN2A/MTAP-deleted cancers [2].

In conclusion, Cdkn2a is a key tumor suppressor gene, with its loss significantly contributing to cancer development, especially melanoma. Research on Cdkn2a-related therapeutic strategies offers potential new avenues for precision medicine in melanoma and understanding the treatment of CDKN2A/MTAP-deleted cancers [1,2].